Drug intelligence / Profile preview

WSK-V101

Development stage: Unknown
Lead developer: Chengdu Weisk Biopharmaceutical
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

WSK-V101 is a recombinant protein-based COVID-19 vaccine developed using the Sf9 insect cell expression system. It targets the SARS-CoV-2 spike (S) protein, acting as an immunostimulant to induce protective immunity against COVID-19. The drug was initially developed by Chengdu Weisk Biopharmaceutical and is being evaluated for use as both a primary and booster immunization in adults, including those with underlying diseases or immunocompromised status. Clinical trials have compared its safety and immunogenicity to bivalent formulations targeting emerging variants[2][3].

Brand names: CoviccineWeiKeXin
Other names: Recombinant COVID-19 vaccine Sf9 Cell

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on WSK-V101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V101.

Explore the full profile